BPC
APLS

Banque Pictet & Cie’s Apellis Pharmaceuticals APLS Stock Holding History

Banque Pictet & Cie’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-97,299
Closed -$3.1M – 397
2024
Q4 		$3.1M Buy
97,299
+23,416
+32% +$704K 0.02% 196
2024
Q3 		$2.13M Buy
+73,883
New +$2.74M 0.02% 191
2023
Q4 		– Sell
-102,242
Closed -$3.89M – 356
2023
Q3 		$3.89M Sell
102,242
-4,893
-5% -$215K 0.05% 163
2023
Q2 		$9.76M Sell
107,135
-31,467
-23% -$2.72M 0.09% 112
2023
Q1 		$9.14M Sell
138,602
-20,323
-13% -$1.17M 0.09% 110
2022
Q4 		$8.22M Sell
158,925
-10,046
-6% -$533K 0.09% 118
2022
Q3 		$11.5M Sell
168,971
-10,579
-6% -$626K 0.13% 92
2022
Q2 		$8.12K Sell
179,550
-9,673
-5% -$441K 0.08% 111
2022
Q1 		$9.61M Buy
189,223
+20,734
+12% +$915K 0.07% 122
2021
Q4 		$7.97M Buy
168,489
+151,606
+898% +$5.97M 0.06% 159
2021
Q3 		$556K Sell
16,883
-5,742
-25% -$323K 0.01% 293
2021
Q2 		$1.43M Buy
22,625
+1,047
+5% +$54K 0.02% 230
2021
Q1 		$926K Buy
+21,578
New +$1.02M 0.01% 254

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Banque Pictet & Cie's APLS Position: Q1 2025 in Review

Banque Pictet & Cie sold out of Apellis Pharmaceuticals (APLS) in Q1 2025, closing a stake of 97,299 shares — an estimated $3.1M sold.

Banque Pictet & Cie first reported a position in APLS in Q1 2021 and held it in 13 quarters. The position peaked at $11.5M in Q3 2022. 255 funds tracked by Wall St. Rank hold APLS as of Q1 2025.

  • Banque Pictet & Cie reported no remaining Apellis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Banque Pictet & Cie sold 97,299 Apellis Pharmaceuticals shares in Q1 2025, an estimated $3.1M.
  • Banque Pictet & Cie first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 13 quarters.
  • Banque Pictet & Cie's Apellis Pharmaceuticals position peaked at $11.5M in Q3 2022.
  • 255 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2025.

Based on Banque Pictet & Cie's 13F filing for Q1 2025, filed 30 Apr 2025.